Показано 0 из 0
Дата |
---|
11:08 |
02.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
19.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.20
|
1.21
|
1.35
|
1.19
|
1.36
|
1.20
|
|
|
30 560 000.00
|
|
1.33
|
1.34
|
1.44
|
1.32
|
1.44
|
1.34
|
|
|
17 330 000.00
|
|
1.40
|
1.41
|
1.46
|
1.39
|
1.54
|
1.41
|
|
|
20 400 000.00
|
|
1.42
|
1.43
|
1.50
|
1.40
|
1.59
|
1.43
|
|
|
37 520 000.00
|
|
1.49
|
1.50
|
1.63
|
1.48
|
1.70
|
1.49
|
|
|
53 560 000.00
|
|
1.63
|
1.64
|
1.61
|
1.54
|
1.79
|
1.63
|
|
|
153 300 000.00
|
|
1.52
|
1.54
|
3.50
|
1.38
|
3.50
|
1.52
|
|
|
225 130 000.00
|
|
3.52
|
3.59
|
3.70
|
3.33
|
3.82
|
3.59
|
|
|
5 100 000.00
|
|
3.68
|
3.70
|
3.99
|
3.63
|
3.99
|
3.68
|
|
|
6 370 000.00
|
|
3.87
|
3.90
|
3.78
|
3.71
|
4.31
|
3.90
|
|
|
16 260 000.00
|
|
HighTide Therapeutics Inc is a company mainly engaged in the manufacture of original new drugs. The Company focuses on metabolic diseases, digestive system diseases and other fields. The Company develops treatments for non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) and other indications.